You searched for " prostate cancer"

140 results found

Are standard repeat biopsies during active surveillance for prostate cancer still necessary?

Active surveillance (AS) has emerged as a key strategy for managing low-risk prostate cancer (PCa), offering an alternative to immediate treatment. Initially, AS relied on prostate specific antigen (PSA) testing, digital rectal examinations (DRE), and systematic biopsies. Early studies using...

Prostate cancer spit test could save the NHS £500 million a year

Thousands of men could have their prostate cancer diagnosed at an earlier stage when it is easier and cheaper to treat, thanks to a new spit test which can be taken at home. An innovative new study launched this week,...

Black men are more at risk from prostate cancer, but we won’t let it stay that way – an update from Prostate Cancer Research

- CHARITY FOCUS - Focusing on all of disease characteristics, societal factors, and better communication gives us real potential to fix a disparity that has persisted for too long. When it comes to health inequity, the numbers are stark. Black...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

PROFILE study seeks to find out why black men develop prostate cancer at twice the rate of other men

A first-of-its-kind study in the UK is aiming to solve the mystery of why black men develop prostate cancer at twice the rate of other men. Funded by Prostate Cancer UK in partnership with Movember, the PROFILE study will look...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Using change theories can help nurses implement better care in prostate cancer

Nurses can help support change in prostate cancer care by understanding change management and models and provide leadership in improving prostate cancer care. An important part of being able to lead change is to understand change theories such as the...

Is TRUS and biopsy obsolete as a diagnostic test for prostate cancer: refining the perineal biopsy technique?

Whilst there has been a dramatic shift in how patients are investigated for potential prostate cancer, transrectal ultrasound (TRUS) and biopsy remains the most commonly used technique for tissue sampling. In this single centre, retrospective analysis, 634 men, over a...

Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study

This study examined a cohort of non-statin using patients who participated in the REDUCE study. The REDUCE study included men who had an elevated prostate specific antigen (PSA) and a negative baseline prostate biopsy who then underwent year two and...

Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade

This is an interesting paper reporting on the use of neoadjuvant androgen blockage in patients with high-risk prostate cancer undergoing radical prostatectomy. Previous work in the literature has shown an improvement in the rate of organ-confined disease and decreased positive...

Trade-offs between risks and benefits of localised prostate cancer treatments – the COMPARE study

We know little about the trade-offs men make when considering the oncological and functional outcomes of individual treatment options for localised prostate cancer, and decisions are often influenced by physician opinion. The likely compromised functional results are viewed as a...

Does empowering men on active surveillance for prostate cancer improve patient compliance and reduce conversion to treatment?

Active surveillance is a major treatment option for patients with favourable prognosis prostate cancer, such as those regarded as Cambridge Prognostic Group (CPG) 1 and 2 [1]. The rationale for this management strategy is the lack of survival benefit from...